Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2019 March;61(1) > Panminerva Medica 2019 March;61(1):42-51

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  HOT TOPICS IN FEMALE INFERTILITY 

Panminerva Medica 2019 March;61(1):42-51

DOI: 10.23736/S0031-0808.18.03537-1

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Advances in ovulation trigger strategies

Carlos DOSOUTO 1, 2 , Thor HAAHR 3, 4, Peter HUMAIDAN 3, 4

1 Department of Obstetrics, Gynecology and Reproductive Medicine, Santa Creu I Sant Pau Hospital, Puigvert Foundation, Barcelona, Spain; 2 Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain; 3 The Fertility Clinic Skive Regional Hospital, Skive, Denmark; 4 Faculty of Health, Aarhus University, Aarhus, Denmark



Ovulation trigger (OT) strategy is a cornerstone in modern patient-tailored in-vitro fertilization treatment, securing the optimal number of mature oocytes retrieved without compromising fertilization, embryo development and euploidy rates. Moreover, the OT strategy is taken into consideration before selecting fresh or frozen embryo transfer (freeze-all) to obtain optimal reproductive outcomes while maintaining a low risk of ovarian hyperstimulation syndrome. Several OT agents have been proposed, however, the most common agents used in modern IVF are human chorionic gonadotropin and gonadotropin-releasing hormone agonist. As no OT agent can be generally recommended for universal use, this review evaluates different OT strategies in different clinical scenarios, discussing both the biological plausibility and the clinical evidence.


KEY WORDS: Chorionic gonadotropin - Fertilization in vitro - Ovarian hyperstimulation syndrome

top of page